Also trades as: NVS (NYSE) · $vol 285M · NVSEF (OTC) · $vol 2M · NVS.TO (TSX) · $vol 0M

CHF 116.34 ($140.43)

-1.72 (-1.46%)

Weekly Expected Move ±6.1%

CHF 102 CHF 109 CHF 116 CHF 123 CHF 130

SIX · Healthcare · Drug Manufacturers - General · Tech Score Sell · Power 38 · CHF 221.1B mcap · 1.86B float · 0.156% daily turnover

Revenue

$57.1B +10.4% ▲

5Y CAGR: +2.7%

Gross Profit

$42.9B +10.2% ▲

5Y CAGR: +4.3%

Operating Income

$17.8B +22.4% ▲

5Y CAGR: +11.9%

Net Income

$14.6B +22.7% ▲

5Y CAGR: +12.7%

EPS (Diluted)

$7.49 +27.6% ▲

5Y CAGR: +16.3%

EBITDA

$24.0B +15.7% ▲

5Y CAGR: +6.8%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$44.0B	$43.5B	$46.7B	$51.7B	$57.1B
YoY Growth	-11.9%	-1.2%	+7.4%	+10.8%	+10.4%
Cost of Revenue	$11.7B	$11.6B	$12.5B	$12.8B	$14.3B
Gross Profit	$32.2B	$31.9B	$34.2B	$38.9B	$42.9B
Gross Margin	73.3%	73.4%	73.3%	75.2%	75.0%
R&D Expenses	$8.6B	$9.2B	$11.4B	$10.0B	$11.2B
SG&A Expenses	$12.8B	$12.2B	$12.5B	$12.6B	$13.9B
Operating Expenses	$22.2B	$23.9B	$24.4B	$24.4B	$25.1B
Operating Income	$10.1B	$7.9B	$9.8B	$14.5B	$17.8B
Operating Margin	22.9%	18.3%	20.9%	28.1%	31.2%
Interest Expense	$905M	$860M	$917M	$1.0B	$1.2B
Income Before Tax	$24.5B	$7.2B	$9.1B	$13.6B	$17.1B
Tax Expense	$1.6B	$1.1B	$551M	$1.7B	$2.5B
Net Income	$24.0B	$7.0B	$14.8B	$11.9B	$14.6B
Net Margin	54.6%	16.0%	31.8%	23.1%	25.6%
EPS (Diluted)	$10.63	$3.17	$7.10	$5.87	$7.49
EBITDA	$30.9B	$14.7B	$18.3B	$20.7B	$24.0B
Shares Outstanding	2.26B	2.20B	2.09B	2.04B	1.96B

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$13.2B	$13.6B	$13.6B	$14.8B	$14.4B	$13.4B	$12.8B	$14.2B
Cost of Revenue	$3.2B	$3.3B	$3.2B	$3.3B	$3.5B	$3.6B	$3.4B	$3.6B
Gross Profit	$9.9B	$10.2B	$10.4B	$11.5B	$10.8B	$9.9B	$9.5B	$10.5B
Gross Margin	75.4%	75.5%	76.3%	77.6%	75.4%	73.4%	73.8%	74.5%
R&D Expenses	$2.4B	$2.8B	$2.4B	$2.7B	$2.9B	$2.9B	$2.7B	$2.7B
SG&A Expenses	$3.1B	$3.5B	$3.1B	$3.4B	$3.3B	$3.5B	$3.1B	$3.2B
Operating Expenses	$6.3B	$6.7B	$5.7B	$6.7B	$6.3B	$6.3B	$5.8B	$5.9B
Operating Income	$3.6B	$3.5B	$4.7B	$4.9B	$4.5B	$3.5B	$3.7B	$4.6B
Operating Margin	27.5%	26.0%	34.2%	32.8%	31.3%	26.4%	28.5%	32.8%
Interest Expense	$272M	$266M	$276M	$299M	$281M	$306M	$336M	$454M
Income Before Tax	$3.4B	$3.3B	$4.4B	$4.5B	$4.2B	$3.2B	$3.8B	$4.2B
Tax Expense	$200M	$465M	$798M	$507M	$266M	$821M	$668M	$994M
Net Income	$3.2B	$2.8B	$3.6B	$4.0B	$3.9B	$2.4B	$3.1B	$3.2B
Net Margin	24.2%	20.8%	26.5%	27.2%	27.4%	18.1%	24.1%	22.7%
EPS (Diluted)	$1.57	$1.41	$1.82	$2.06	$2.00	$1.26	$1.61	$1.68
EBITDA	$5.6B	$5.2B	$5.7B	$6.1B	$5.8B	$5.1B	$5.3B	$5.8B
Shares Outstanding	2.03B	2.00B	1.98B	1.96B	1.96B	1.93B	1.92B	1.91B

NOVN.SW SIX